<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00287872</url>
  </required_header>
  <id_info>
    <org_study_id>J0456 CDR0000450772</org_study_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>JHOC-J0456</secondary_id>
    <secondary_id>JHOC-04063003</secondary_id>
    <secondary_id>MILLENNIUM-JHOC-J0456</secondary_id>
    <nct_id>NCT00287872</nct_id>
  </id_info>
  <brief_title>Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma</brief_title>
  <official_title>VELCADE (Bortezomib) and Thalidomide in Newly Diagnosed Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes
      needed for cell growth. Thalidomide may stop the growth of cancer cells by blocking blood
      flow to the cancer. Giving bortezomib together with thalidomide may kill more cancer cells.

      PURPOSE: This phase II trial is studying how well giving bortezomib together with thalidomide
      works in treating patients with newly diagnosed stage II or stage III multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the antitumor efficacy of bortezomib and thalidomide in patients with newly
           diagnosed stage II or III multiple myeloma.

        -  Determine the incidence and severity of peripheral motor/sensory neuropathy in patients
           treated with this regimen.

        -  Assess the ability to mobilize and collect stem cells in patients who undergo future
           autologous peripheral stem cell transplantation.

        -  Determine the time to response in patients treated with this regimen.

        -  Assess the quality of life of patients treated with this regimen.

      OUTLINE: This is an open-label study.

      Patients receive bortezomib IV on days 1, 4, 8, and 11 and oral thalidomide once daily on
      days 1-21. Treatment repeats every 21 days for at least 4 courses. Patients who plan to
      undergo transplantation AND achieve ≥ 50% reduction in the tumor burden proceed to
      transplantation off study. Patients who do not undergo transplantation receive 2 additional
      courses of therapy beyond best response for up to 8 courses in the absence of disease
      progression or unacceptable toxicity.

      Patients who achieve at least a partial response after completion of treatment may receive
      maintenance therapy comprising bortezomib IV every 2 months and oral thalidomide* once daily
      OR twice every 2 months (i.e., the day before and the day of bortezomib administration) in
      the absence of disease progression or unacceptable toxicity.

      NOTE: *For patients who had previously discontinued thalidomide, maintenance therapy may
      consist of bortezomib only.

      Quality of life is assessed at baseline, at the beginning of each study course, and after
      completion of study treatment.

      After completion of study treatment, patients are followed every 3 months.

      PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Response to Treatment</measure>
    <time_frame>1-6 months</time_frame>
    <description>Clinical evaluations of disease response were determined with each cycle. Bone marrow biopsies were done at baseline and at study termination. Clinical responses were defined by the International Myeloma Working Group criteria: Stringent Complete Response (SCR), CR and normal free light chain ratio and no clonal cells in bone marrow; Complete Response (CR), Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; Very Good Partial Response (VGPR), Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level &lt; 100 mg/24 hours; Partial Response (PR), ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to &lt; 200 mg/24 hours. Objective response is defined as a best overall response of SCR, CR, VGPR, or PR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peripheral Motor and Sensory Neuropathy (Grade 2 and Higher)</measure>
    <time_frame>1-6 months</time_frame>
    <description>Neuropathy was monitored using Total Neuropathy Score reduced (TNSr).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mobilization of Stem Cells in Patients Proceeding to Autologous Peripheral Stem Transplantation</measure>
    <time_frame>1-6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Time to Response</measure>
    <time_frame>1-6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>0-6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Bortezomib and Thalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will receive Bortezomib on days 1, 4, 8 and 11 of each 21 day cycle in combination with daily oral Thalidomide.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <arm_group_label>Bortezomib and Thalidomide</arm_group_label>
    <other_name>VELCADE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
    <arm_group_label>Bortezomib and Thalidomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Newly diagnosed Salmon-Durie stage II or III multiple myeloma

               -  Untreated disease OR patient underwent prior therapy for this cancer that lasted
                  no more than 2 weeks

          -  Measurable paraprotein in serum or urine (serum free-lite assay measurement allowed)

          -  No evidence of cord compression requiring concurrent steroids

        PATIENT CHARACTERISTICS:

          -  Creatinine clearance ≥ 30 mL/min

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use 2 methods of contraception, including ≥ 1 highly effective
             method, 4 weeks before, during, and for ≥ 4 weeks after completion of study treatment

          -  No known HIV positivity

          -  No peripheral neuropathy ≥ grade 2

          -  No hypersensitivity to bortezomib, boron, or mannitol

        PRIOR CONCURRENT THERAPY:

          -  No prior bortezomib

          -  More than 28 days since prior regimens with a duration of &gt; 1 week but ≤ 2 weeks

          -  No steroids within 14 days prior to study entry

          -  No concurrent corticosteroids except for the treatment of a nonmalignant condition

               -  May not exceed the equivalent dose of prednisone 10 mg/day

          -  No concurrent chemotherapy, immunotherapy, radiotherapy, or surgery

          -  No other concurrent investigational agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivan Borrello, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Ghosh N, Ye X, Ferguson A, Huff CA, Borrello I. Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma. Br J Haematol. 2011 Mar;152(5):593-9. doi: 10.1111/j.1365-2141.2010.08534.x. Epub 2011 Jan 17.</citation>
    <PMID>21241279</PMID>
  </results_reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2006</study_first_submitted>
  <study_first_submitted_qc>February 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2006</study_first_posted>
  <results_first_submitted>June 25, 2014</results_first_submitted>
  <results_first_submitted_qc>June 25, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 23, 2014</results_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bortezomib and Thalidomide</title>
          <description>The patients will receive Bortezomib on days 1, 4, 8 and 11 of each 21 day cycle in combination with daily oral Thalidomide.
bortezomib
thalidomide</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bortezomib and Thalidomide</title>
          <description>The patients will receive Bortezomib on days 1, 4, 8 and 11 of each 21 day cycle in combination with daily oral Thalidomide.
bortezomib
thalidomide</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.4" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Response to Treatment</title>
        <description>Clinical evaluations of disease response were determined with each cycle. Bone marrow biopsies were done at baseline and at study termination. Clinical responses were defined by the International Myeloma Working Group criteria: Stringent Complete Response (SCR), CR and normal free light chain ratio and no clonal cells in bone marrow; Complete Response (CR), Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; Very Good Partial Response (VGPR), Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level &lt; 100 mg/24 hours; Partial Response (PR), ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to &lt; 200 mg/24 hours. Objective response is defined as a best overall response of SCR, CR, VGPR, or PR.</description>
        <time_frame>1-6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bortezomib and Thalidomide</title>
            <description>The patients will receive Bortezomib on days 1, 4, 8 and 11 of each 21 day cycle in combination with daily oral Thalidomide.
bortezomib
thalidomide</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response to Treatment</title>
          <description>Clinical evaluations of disease response were determined with each cycle. Bone marrow biopsies were done at baseline and at study termination. Clinical responses were defined by the International Myeloma Working Group criteria: Stringent Complete Response (SCR), CR and normal free light chain ratio and no clonal cells in bone marrow; Complete Response (CR), Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; Very Good Partial Response (VGPR), Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level &lt; 100 mg/24 hours; Partial Response (PR), ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to &lt; 200 mg/24 hours. Objective response is defined as a best overall response of SCR, CR, VGPR, or PR.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.5" lower_limit="62" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peripheral Motor and Sensory Neuropathy (Grade 2 and Higher)</title>
        <description>Neuropathy was monitored using Total Neuropathy Score reduced (TNSr).</description>
        <time_frame>1-6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bortezomib and Thalidomide</title>
            <description>The patients will receive Bortezomib on days 1, 4, 8 and 11 of each 21 day cycle in combination with daily oral Thalidomide.
bortezomib
thalidomide</description>
          </group>
        </group_list>
        <measure>
          <title>Peripheral Motor and Sensory Neuropathy (Grade 2 and Higher)</title>
          <description>Neuropathy was monitored using Total Neuropathy Score reduced (TNSr).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mobilization of Stem Cells in Patients Proceeding to Autologous Peripheral Stem Transplantation</title>
        <time_frame>1-6 months</time_frame>
        <population>Analysis not completed as the information was not relevant since no patients went on to transplant.</population>
        <group_list>
          <group group_id="O1">
            <title>Bortezomib and Thalidomide</title>
            <description>The patients will receive Bortezomib on days 1, 4, 8 and 11 of each 21 day cycle in combination with daily oral Thalidomide.
bortezomib
thalidomide</description>
          </group>
        </group_list>
        <measure>
          <title>Mobilization of Stem Cells in Patients Proceeding to Autologous Peripheral Stem Transplantation</title>
          <population>Analysis not completed as the information was not relevant since no patients went on to transplant.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Time to Response</title>
        <time_frame>1-6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bortezomib and Thalidomide</title>
            <description>The patients will receive Bortezomib on days 1, 4, 8 and 11 of each 21 day cycle in combination with daily oral Thalidomide.
bortezomib thalidomide</description>
          </group>
        </group_list>
        <measure>
          <title>The Time to Response</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0.5" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life</title>
        <time_frame>0-6 months</time_frame>
        <population>Analysis not done on subject population.</population>
        <group_list>
          <group group_id="O1">
            <title>Bortezomib and Thalidomide</title>
            <description>The patients will receive Bortezomib on days 1, 4, 8 and 11 of each 21 day cycle in combination with daily oral Thalidomide.
bortezomib
thalidomide</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life</title>
          <population>Analysis not done on subject population.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Bortezomib and Thalidomide</title>
          <description>The patients will receive Bortezomib on days 1, 4, 8 and 11 of each 21 day cycle in combination with daily oral Thalidomide.
bortezomib
thalidomide</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>nausea &amp; vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>neutropenic fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="40" subjects_affected="19" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>diarrhoea</sub_title>
                <counts group_id="E1" events="29" subjects_affected="15" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="48" subjects_affected="22" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>peripheral neuropathy</sub_title>
                <counts group_id="E1" events="75" subjects_affected="25" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ivan Borrello</name_or_title>
      <organization>The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</organization>
      <phone>(410) 955-4967</phone>
      <email>iborrell@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

